Ahmed Shelbaya

5PUBLICATIONS
19CO-AUTHORS
Social epidemiologyRheumatology and arthritisCancer therapy (excl. chemotherapy and radiation therapy)Not-for-profit finance and riskRegenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Oct 16, 2026
Impact of the Sociodemographic Index on Efficacy/Safety of Tofacitinib in Patients with Rheumatoid Arthritis: Post Hoc Analysis of Phase 2/3/3b/4 Studies.

|Oct 30, 2025
Characterization of Second-Line Therapy After First JAK Inhibitor Use: Results From the CorEvitas Rheumatoid Arthritis Registry.

Joshua F Baker, Kristi V Mizelle, Wassim Saikali

|Dec 20, 2024
Effectiveness of tofacitinib versus tumor necrosis factor inhibitors and in those receiving tofacitinib as different lines of therapy in patients with rheumatoid arthritis: results from the United States CorEvitas Rheumatoid Arthritis Registry.

Leslie R Harrold, Clifton O Bingham, Janet E Pope

|May 20, 2024
Clinical and Economic Value of a Biosimilar Portfolio to Stakeholders: An Integrative Literature Review.

Grace E Fox, Mark Bernauer, Jennifer M Stephens

|Jul 14, 2021
Real-world use and acceptance of biosimilar monoclonal antibodies of rituximab in oncology practice in the USA.

Ahmed Shelbaya, John M Kelton, Jeffrey Thompson

Pageof 1

Frequent Collaborators

2 joint publications

Karim R Masri

1 joint publications

Martine C Maculaitis

1 joint publications

Jingyan Yang

1 joint publications

Grace E Fox